3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
7
Lung Neoplasms
6
Colorectal Neoplasms
5
Prostatic Neoplasms
3
Smoking Cessation
2
Neoplasm Metastasis
2
Lymphoma
2
Colonic Neoplasms
2
Breast Neoplasms
2
Uveal Melanoma
1
Stomach Neoplasms
1
Solitary Pulmonary Nodule
1
Retroviridae Infections
1
Pulmonary Disease, Chronic Obstructive
1
Pancreatic cancer, adult
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplasm, Residual
1
Multiple Myeloma
1
Motor Activity
1
Leukemia
1
Inflammation
1
Glioblastoma
1
Esophageal Neoplasms
1
Dyspnea
1
Disease
1
Colorectal Neoplasms, Hereditary Nonpolyposis
1
Cardiovascular Diseases
1
Cardiotoxicity
1
Carcinoma, Transitional Cell
1
Interventions
pembrolizumab
44
Gemcitabine
23
enfortumab vedotin
21
Nivolumab
20
Cisplatin
17
avelumab
16
Magnetic Resonance Spectroscopy
15
Carboplatin
14
atezolizumab
13
Specimen Handling
12
Docetaxel
11
sacituzumab govitecan
9
Paclitaxel
8
Ipilimumab
8
durvalumab
6
Mitomycin
5
Fluorodeoxyglucose F18
5
cabozantinib
4
Taxes
4
toripalimab
3
pemigatinib
3
erdafitinib
3
X-Rays
3
Radiosurgery
3
Platinum
3
Pemetrexed
3
Immunoglobulin G
3
CTLA-4 Antigen
3
Biopsy
3
ALT-803
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
Hematologic Tests
×
1 year
×
Clear all
NCT04566029
2025-12-10
AMI
Centre Hospitalier Universitaire de NÄ«mes
Completed
40 enrolled